[go: up one dir, main page]

EP3092250A4 - Polynucleotides for the in vivo production of antibodies - Google Patents

Polynucleotides for the in vivo production of antibodies Download PDF

Info

Publication number
EP3092250A4
EP3092250A4 EP15735068.7A EP15735068A EP3092250A4 EP 3092250 A4 EP3092250 A4 EP 3092250A4 EP 15735068 A EP15735068 A EP 15735068A EP 3092250 A4 EP3092250 A4 EP 3092250A4
Authority
EP
European Patent Office
Prior art keywords
polynucleotides
antibodies
vivo production
vivo
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15735068.7A
Other languages
German (de)
French (fr)
Other versions
EP3092250A1 (en
Inventor
Joseph Beene BOLEN
Axel Bouchon
Giuseppe Ciaramella
Eric Yi-Chun Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
Moderna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moderna Therapeutics Inc filed Critical Moderna Therapeutics Inc
Publication of EP3092250A1 publication Critical patent/EP3092250A1/en
Publication of EP3092250A4 publication Critical patent/EP3092250A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP15735068.7A 2014-01-08 2015-01-08 Polynucleotides for the in vivo production of antibodies Withdrawn EP3092250A4 (en)

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US201461924779P 2014-01-08 2014-01-08
US201461924817P 2014-01-08 2014-01-08
US201461924804P 2014-01-08 2014-01-08
US201461924768P 2014-01-08 2014-01-08
US201461924802P 2014-01-08 2014-01-08
US201461924776P 2014-01-08 2014-01-08
US201461924773P 2014-01-08 2014-01-08
US201461924820P 2014-01-08 2014-01-08
US201461924795P 2014-01-08 2014-01-08
US201461924807P 2014-01-08 2014-01-08
US201461924846P 2014-01-08 2014-01-08
US201461924783P 2014-01-08 2014-01-08
US201461924799P 2014-01-08 2014-01-08
US201461924787P 2014-01-08 2014-01-08
US201461924754P 2014-01-08 2014-01-08
US201461924805P 2014-01-08 2014-01-08
US201461924770P 2014-01-08 2014-01-08
US201461924850P 2014-01-08 2014-01-08
US201461924819P 2014-01-08 2014-01-08
US201461924841P 2014-01-08 2014-01-08
US201461924775P 2014-01-08 2014-01-08
US201461924834P 2014-01-08 2014-01-08
US201461924774P 2014-01-08 2014-01-08
US201461924763P 2014-01-08 2014-01-08
US201461924767P 2014-01-08 2014-01-08
US201461924810P 2014-01-08 2014-01-08
US201461924827P 2014-01-08 2014-01-08
US201461924791P 2014-01-08 2014-01-08
US201461924781P 2014-01-08 2014-01-08
US201461924811P 2014-01-08 2014-01-08
US201461924812P 2014-01-08 2014-01-08
US201461993715P 2014-05-15 2014-05-15
PCT/US2015/010547 WO2015105926A1 (en) 2014-01-08 2015-01-08 Polynucleotides for the in vivo production of antibodies

Publications (2)

Publication Number Publication Date
EP3092250A1 EP3092250A1 (en) 2016-11-16
EP3092250A4 true EP3092250A4 (en) 2017-05-24

Family

ID=53524318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15735068.7A Withdrawn EP3092250A4 (en) 2014-01-08 2015-01-08 Polynucleotides for the in vivo production of antibodies

Country Status (2)

Country Link
EP (1) EP3092250A4 (en)
WO (1) WO2015105926A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG190679A1 (en) 2010-10-01 2013-07-31 Jason Schrum Engineered nucleic acids and methods of use thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015513913A (en) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotide
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
LT3019619T (en) 2013-07-11 2021-12-10 Modernatx, Inc. COMPOSITIONS INCLUDING SYNTHETIC POLYNUCLEOTIDES CODING CRISPR-RELATED PROTEINS AND SYNTHETIC SCHEMES AND THEIR USES
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
US20170210788A1 (en) * 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
TWI797060B (en) 2015-08-04 2023-04-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
AU2016324463B2 (en) 2015-09-17 2022-10-27 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
US10849920B2 (en) 2015-10-05 2020-12-01 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017117218A1 (en) * 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
US10532109B2 (en) 2016-05-18 2020-01-14 Arizona Board Of Regents On Behalf Of Arizona State University Peptide-DNA chimeras for treatment of HER overexpressing cancers
MX2019000205A (en) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Compositions and methods related to therapeutic cell systems expressing exogenous rna.
WO2018021188A1 (en) * 2016-07-26 2018-02-01 学校法人日本大学 Therapeutic agent for periodontitis and composition for treating periodontitis
AU2017356190B2 (en) * 2016-11-10 2024-11-21 Translate Bio, Inc. Subcutaneous delivery of messenger RNA
US20190351055A1 (en) * 2016-11-16 2019-11-21 University Of Baltimore, Maryland Methods for Treating Bone-Related Disorders
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
MA51523A (en) 2018-01-05 2020-11-11 Modernatx Inc POLYNUCLEOTIDES CODING ANTI-BODY ANTI-CHIKUNGUNYA VIRUS
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
EP4172194A1 (en) * 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
US20240254245A1 (en) * 2021-05-12 2024-08-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
WO2023031394A1 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
JP2024537804A (en) * 2021-09-29 2024-10-16 モードエックス セラピューティクス インコーポレイテッド Antigen-binding polypeptides, antigen-binding polypeptide complexes, and methods of using same
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
KR20230121575A (en) 2022-02-10 2023-08-18 주식회사 아피셀테라퓨틱스 Stefin A protein variants specifically binding to CD40L, and uses thereof
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075514A2 (en) * 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20130196377A1 (en) * 2011-12-26 2013-08-01 Samsung Electronics Co., Ltd. Protein complex and method of preparing same
US20130195867A1 (en) * 2007-01-09 2013-08-01 Curevac Gmbh Rna-coded antibody
WO2013151666A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014152774A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075514A2 (en) * 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20130195867A1 (en) * 2007-01-09 2013-08-01 Curevac Gmbh Rna-coded antibody
US20130196377A1 (en) * 2011-12-26 2013-08-01 Samsung Electronics Co., Ltd. Protein complex and method of preparing same
WO2013151666A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014152774A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015105926A1 *
TORBEN GJETTING ET AL: "International Journal of Nanomedicine", INTERNATIONAL JOURNAL OF NANOMEDICINE, 1 January 2010 (2010-01-01), pages 371 - 383, XP055609161, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950395/pdf/ijn-5-371.pdf> [retrieved on 20190726] *
XIAOYING CHEN ET AL: "Fusion protein linkers: Property, design and functionality", NIH PUBLIC ACCESS AUTHOR MANUSCRIPT, 1 October 2013 (2013-10-01), pages 1 - 32, XP055341428, DOI: 10.1016/j.addr.2012.09.039 *

Also Published As

Publication number Publication date
EP3092250A1 (en) 2016-11-16
WO2015105926A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
EP3092250A4 (en) Polynucleotides for the in vivo production of antibodies
EP3212231A4 (en) Anti-tim-3 antibodies
EP3212229A4 (en) Anti-tim-3 antibodies
EP3240564A4 (en) Methods of producing long acting ctp-modified polypeptides
EP3192864A4 (en) Method for producing cerebellar progenitor tissue
EP3166931A4 (en) An improved process for the preparation of enzalutamide
EP3119806A4 (en) Il-21 antibodies
EP3237195A4 (en) Methods for producing pressware
EP3177650A4 (en) Anti-ceramide antibodies
HUP1400114A2 (en) Method for the production of peptides
EP3151857A4 (en) Anti-blys antibodies
EP3181709A4 (en) Steel-strip production apparatus
IL248267B (en) Process for the preparation of substituted cycloserines
EP3138903A4 (en) Cells for producing human antibody
EP3147369A4 (en) Fibroin-like protein production method
SI3160985T1 (en) Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
EP3112463A4 (en) Novel anti-presepsin antibody
EP3233120A4 (en) Il-21 antibodies
EP3127943A4 (en) Process for producing nanoparticles
EP3107883A4 (en) Process for the manufacture of hydrochlorofluoroolefins
EP3227246B8 (en) Oxy-calcination process
EP3182981A4 (en) Process for the production of isomaltooligosaccharides
IL247443B (en) Process for the preparation of 5-fluorotryptophol
EP3242937A4 (en) Methods for producing abienol
EP3099655A4 (en) Process for the manufacture of hydrochlorofluoroolefins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170424

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 19/34 20060101ALI20170418BHEP

Ipc: C07K 16/18 20060101AFI20170418BHEP

Ipc: A61K 39/395 20060101ALI20170418BHEP

Ipc: C07K 16/28 20060101ALI20170418BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MODERNATX, INC.

17Q First examination report despatched

Effective date: 20190802

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20191017